Literature DB >> 22772150

Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine.

Moritz Wagner1, Rene Schilling, Patrick Doeblin, Alexander Huppertz, Reny Luhur, Carsten Schwenke, Martin Maurer, Bernd Hamm, Matthias Taupitz, Tahir Durmus.   

Abstract

OBJECTIVES: To compare 0.15 mmol/kg gadobutrol for late gadolinium enhancement (LGE) imaging of chronic myocardial infarction with a relaxivity-adjusted dose of gadoterate meglumine (Gd-DOTA).
METHODS: Seventeen patients with suspected chronic myocardial infarction underwent LGE imaging at 1.5 T, acquiring an inversion-recovery-prepared gradient echo sequence 15 min after contrast agent administration. Each patient underwent LGE imaging twice, once after administration of 0.15 mmol/kg gadobutrol (r1 = 5.2 l mmol(-1) s(-1)) and after 0.22 mmol/kg Gd-DOTA (r1 = 3.6 l mmol(-1) s(-1)). Two readers independently determined infarct size and contrast-to-noise ratios of infarcted myocardium to remote myocardium (CNR(remote)) and to the left ventricular lumen (CNR(lumen)).
RESULTS: LGE was present in 14 patients. Infarct sizes determined after administration of gadobutrol [23.4 ml; 95 % CI (14.4; 32.5)] and Gd-DOTA [22.1 ml; 95 % CI (13.0; 31.1)] were not statistically different (P = 0.22). The CNR(remote) of LGE in infarcted myocardium on gadobutrol- and Gd-DOTA-enhanced images was 44.1 [95 % CI (31.0; 57.1)] and 45.2 [95 % CI (32.2; 58.3)], respectively (P = 0.73). CNR(lumen) was significantly higher on gadobutrol-enhanced LGE images [12.7; 95 % CI (2.5; 23.0) versus 6.8; 95 % CI (-3.5; 17.0); P = 0.02].
CONCLUSION: At relaxivity-adjusted doses, gadobutrol and Gd-DOTA yielded similar infarct sizes with superior contrast between infarcted myocardium and left ventricular lumen on gadobutrol-enhanced images.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772150     DOI: 10.1007/s00330-012-2563-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  High-resolution myocardial stress perfusion at 3 T in patients with suspected coronary artery disease.

Authors:  Carsten Meyer; Katharina Strach; Daniel Thomas; Harold Litt; Claas P Nähle; Klaus Tiemann; Ulrich Schwenger; Hans H Schild; Torsten Sommer
Journal:  Eur Radiol       Date:  2007-09-13       Impact factor: 5.315

2.  Using a contrast-enhanced imaging sequence at 3-minute delay in 3-T magnetic resonance imaging for acute infarct evaluation.

Authors:  Alexandre Comte; Bruno Kastler; Laurent Laborie; Georges Hadjidekov; Nicolas Meneveau; Hatem Boulahdour
Journal:  Invest Radiol       Date:  2008-09       Impact factor: 6.016

3.  The role of cardiac magnetic resonance imaging following acute myocardial infarction.

Authors:  Dennis T L Wong; James D Richardson; Rishi Puri; Adam J Nelson; Angela G Bertaso; Karen S L Teo; Matthew I Worthley; Stephen G Worthley
Journal:  Eur Radiol       Date:  2012-03-25       Impact factor: 5.315

4.  Delayed enhancement imaging of myocardial viability: low-dose high-pitch CT versus MRI.

Authors:  Robert Goetti; Gudrun Feuchtner; Paul Stolzmann; Olivio F Donati; Monika Wieser; André Plass; Thomas Frauenfelder; Sebastian Leschka; Hatem Alkadhi
Journal:  Eur Radiol       Date:  2011-05-15       Impact factor: 5.315

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.

Authors:  Tahir Durmus; Rene Schilling; Patrick Doeblin; Alexander Huppertz; Bernd Hamm; Matthias Taupitz; Moritz Wagner
Journal:  Invest Radiol       Date:  2012-03       Impact factor: 6.016

7.  Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate.

Authors:  Thomas Schlosser; Peter Hunold; Christoph U Herborn; Heidrun Lehmkuhl; Alexander Lind; Sandra Massing; Jörg Barkhausen
Journal:  Radiology       Date:  2005-07-29       Impact factor: 11.105

8.  Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.

Authors:  Kerstin U Bauner; Maximilian F Reiser; Armin M Huber
Journal:  Invest Radiol       Date:  2009-02       Impact factor: 6.016

9.  Reperfused and nonreperfused myocardial infarction: diagnostic potential of Gd-DTPA--enhanced MR imaging.

Authors:  A de Roos; A C van Rossum; E van der Wall; S Postema; J Doornbos; N Matheijssen; P R van Dijkman; F C Visser; A E van Voorthuisen
Journal:  Radiology       Date:  1989-09       Impact factor: 11.105

Review 10.  Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience.

Authors:  Constantina Chrysochou; David L Buckley; Paul Dark; Alistair Cowie; Philip A Kalra
Journal:  J Magn Reson Imaging       Date:  2009-04       Impact factor: 4.813

View more
  7 in total

1.  [Cardiac magnetic resonance imaging: from imaging to diagnosis].

Authors:  M Gutberlet
Journal:  Radiologe       Date:  2013-11       Impact factor: 0.635

2.  Comprehensive evaluation of macroscopic and microscopic myocardial fibrosis by cardiac MR: intra-individual comparison of gadobutrol versus gadoterate meglumine.

Authors:  Amir Ali Rahsepar; Ahmadreza Ghasemiesfe; Kenichiro Suwa; Ryan S Dolan; Monda L Shehata; Monica J Korell; Nivedita K Naresh; Michael Markl; Jeremy D Collins; James C Carr
Journal:  Eur Radiol       Date:  2019-01-07       Impact factor: 5.315

3.  Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.

Authors:  Dongting Liu; Xiaohai Ma; Jiayi Liu; Lei Zhao; Hui Chen; Lei Xu; Zhonghua Sun; Zhanming Fan
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-13       Impact factor: 2.357

Review 4.  Imaging the myocardial ischemic cascade.

Authors:  Arthur E Stillman; Matthijs Oudkerk; David A Bluemke; Menko Jan de Boer; Jens Bremerich; Ernest V Garcia; Matthias Gutberlet; Pim van der Harst; W Gregory Hundley; Michael Jerosch-Herold; Dirkjan Kuijpers; Raymond Y Kwong; Eike Nagel; Stamatios Lerakis; John Oshinski; Jean-François Paul; Riemer H J A Slart; Vinod Thourani; Rozemarijn Vliegenthart; Bernd J Wintersperger
Journal:  Int J Cardiovasc Imaging       Date:  2018-03-19       Impact factor: 2.357

Review 5.  Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies: Insights From Randomized Controlled Trials.

Authors:  Heerajnarain Bulluck; Matthew Hammond-Haley; Shane Weinmann; Roberto Martinez-Macias; Derek J Hausenloy
Journal:  JACC Cardiovasc Imaging       Date:  2017-03

6.  Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T.

Authors:  Moritz Wildgruber; Thomas Stadlbauer; Michael Rasper; Alexander Hapfelmeier; Otto Zelger; Hans-Henning Eckstein; Martin Halle; Ernst J Rummeny; Armin M Huber
Journal:  Invest Radiol       Date:  2014-11       Impact factor: 6.016

7.  Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI.

Authors:  Jiyeon Lim; Eun-Ah Park; Yong Sub Song; Whal Lee
Journal:  Korean J Radiol       Date:  2018-04-06       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.